Herantis Pharma Oyj
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinic… Read more
Herantis Pharma Oyj (HRTIS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -1.937x
Based on the latest financial reports, Herantis Pharma Oyj (HRTIS) has a cash flow conversion efficiency ratio of -1.937x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.39 Million) by net assets (€1.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Herantis Pharma Oyj - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Herantis Pharma Oyj's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Herantis Pharma Oyj Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Herantis Pharma Oyj ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Land and Houses Freehold and Leasehold Property Fund
BK:LHPF
|
0.004x |
|
Metro Performance Glass Ltd
AU:MPP
|
0.093x |
|
Luxury Real Estate Investment Fund
BK:LUXF
|
-0.005x |
|
Coreana Cosmetics Co.Ltd
KQ:027050
|
-0.009x |
|
JLS Co.Ltd
KQ:040420
|
0.043x |
|
JITF Infralogistics Limited
NSE:JITFINFRA
|
0.323x |
|
People's Bank of Commerce
PINK:PBCO
|
N/A |
|
San Leon Energy plc
OTCGREY:SLGYF
|
0.000x |
Annual Cash Flow Conversion Efficiency for Herantis Pharma Oyj (2012–2024)
The table below shows the annual cash flow conversion efficiency of Herantis Pharma Oyj from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-243.00K | €-6.54 Million | 26.934x | +2845.91% |
| 2023-12-31 | €4.73 Million | €-4.64 Million | -0.981x | -100.66% |
| 2022-12-31 | €-60.28K | €-8.94 Million | 148.365x | +927.89% |
| 2021-12-31 | €554.30K | €-9.93 Million | -17.921x | -1488.32% |
| 2020-12-31 | €7.59 Million | €-8.56 Million | -1.128x | +64.95% |
| 2019-12-31 | €1.85 Million | €-5.96 Million | -3.219x | -107.70% |
| 2018-12-31 | €-89.29K | €-3.73 Million | 41.801x | +6678.70% |
| 2017-12-31 | €4.09 Million | €-2.60 Million | -0.635x | +67.04% |
| 2016-12-31 | €1.57 Million | €-3.04 Million | -1.928x | -56.32% |
| 2015-12-31 | €6.00 Million | €-7.40 Million | -1.233x | -514.33% |
| 2014-12-31 | €21.72 Million | €-4.36 Million | -0.201x | +89.26% |
| 2013-12-31 | €120.00K | €-224.21K | -1.868x | -101.18% |
| 2012-12-31 | €-3.37K | €-533.42K | 158.097x | -- |